An interventional study of VIVO-assisted mapping in Ventricular Tachycardia (VT) and Catheter Ablation, sponsored by University of Warwick. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by University of Warwick · Not applicable, Interventional, and Supportive care
Ventricular tachycardia (VT) is an abnormal and dangerous heart rhythm affecting the lower chambers of the heart (the ventricles). Patients with structural heart disease caused by previous heart attacks are at an increased risk of developing VT. Current guidelines recommend that patients who develop this abnormal heart rhythm are considered for invasive catheter ablation (ICA). This is an invasive procedure where specialised catheters and a 3D electro anatomical mapping (EAM) system are used to identify the region of the heart responsible for the VT, which is then treated by tissue heating or freezing (ablation). Although significant improvements have been made in both mapping and ablation technologies, these procedures remain technically challenging and time consuming.
View into ventricular onset (VIVO, Catheter Precision) is a non-invasive, mapping system already being used within the NHS. It uses images from previous heart scans, a picture of the patient's chest (taken at the start of the procedure) and a 12-lead electrocardiogram (ECG) tracing, to locate where the VT is coming from. The VIVO map can therefore highlight the likely region of interest for ICA prior to invasive EAM.
This study will be a prospective, multi-centre, two-arm, non-blinded, randomised controlled trial (RCT). Patients will be evenly randomised (50:50) into a standard VT ablation group and a VIVO guided ablation group. In the VIVO guided ablation group, invasive EAM will be restricted to the region of interest identified using the VIVO map, rather than whole chamber mapping required for standard ablation. The primary objective will be to determine if the VIVO non-invasive mapping system reduces procedure duration and therefore improves workflow efficiency. Secondary objectives will assess the procedural success, safety and patient perceived health benefits of a VIVO guided ablation versus standard ablation.
451 studies on the registry are indexed under Tachycardia, Ventricular; 120 are open to participants now.
This study's planned enrollment of 110 is above the median of 71 across 280 interventional studies indexed under Tachycardia, Ventricular.
Browse Tachycardia, Ventricular studies →University of Warwick is the lead sponsor of 26 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: VIVO-assisted mapping
VIVO (or View Into Ventricular Onset) is a non-invasive cardiac mapping technology which uses images from patients' previous heart scans, a picture of their chest (taken at the start of the procedure) and a tracing of their VT, to locate where the ventricular tachycardia is coming from.
Total procedural time (minutes)
the time from first incision (needle to skin) to the removal of the venous/arterial sheaths
Time frame: day of procedure
Procedure time in VT (minutes)
Time frame: during VT ablation procedure
Mapping time (minutes)
Time frame: during VT ablation procedure
Ablation time (minutes).
Time frame: During VT ablation procedure
Total number of ablation applications
Time frame: During ablation procedure
Total number of shocks delivered
Time frame: during the VT ablation procedure
Number of Participants with VT non-inducibility determined by Programmed Ventricular Stimulation (PVS)
Time frame: during VT ablation procedure
Number of Participants with substrate modification confirmed by remap
Time frame: during the VT ablation procedure
Total number of ICD/CRTD determined appropriate shock events
Total number of ICD/CRTD shock events per patient will be documented on database
Time frame: day of procedure to 6 months post-procedure
Total number of ICD/CRTD determined anti-tachycardia pacing (ATP) events
Total number of ICD/CRTD ATP events per patient will be documented on database
Time frame: day of procedure to 6 months post-procedure
Total number of VT episodes as determined from ICD/CRTD
Time frame: day of procedure to 6 months post-procedure
Recognised VT ablation procedural complications
Time frame: day of the procedure to 30 days after the VT ablation procedure
Total number of hospitalisations
Total number of hospitalisation events per patient will be documented on database
Time frame: day of the procedure to 30 days after the VT ablation procedure
Mortality
Time frame: day of the procedure to 30 days after the VT ablation procedure
Perceived health benefit of treatment
EQ-5D-5L
Time frame: at baseline and 6 months
Plan to share: Yes — Anonymised participant data will be made available by the Sponsor following official request.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Warwick